Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 777 of 5804
-
HPV vaccine shows promise for chinese women and girls in large trial
⭐️ VACCINE ⭐️ CompletedThis study investigates the immunogenicity and safety of the 9vHPV vaccine in healthy Chinese females 9 to 45 years of age. The study consists of Stage I (Day 1 to Month 7) and Stage II (post Month 7 to Month 60). Stage II will report the long-term immunogenicity and safety in th…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThe main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, …
Phase: PHASE1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New biologic drug aims to ease pain in hidden arthritis
Disease control CompletedThe purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug shows promise for back pain from ankylosing spondylitis
Disease control CompletedThe purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Eye drops may curb worsening nearsightedness in kids
Disease control CompletedMyopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lea…
Phase: PHASE3 • Sponsor: Sydnexis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New immune cell therapy takes on Hard-to-Treat myeloma
Disease control TerminatedThis phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune cells can …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for rare seizure patients: Long-Term drug safety confirmed
Disease control CompletedThis is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
Phase: PHASE3 • Sponsor: Zogenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could cheap steroids help hearts in shock?
Disease control CompletedThe purpose of this randomized controlled trial is to evaluate the hemodynamic effect of low dose corticosteroid therapy (hydrocortisone and fludrocortisone) in the treatment of adult cardiogenic shock.
Phase: PHASE3 • Sponsor: CMC Ambroise Paré • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Lung cancer showdown: which targeted pill works better after crizotinib fails?
Disease control CompletedBrigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brig…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 16:05 UTC
-
New stem cell transplant trial aims to control tough lymphoma
Disease control Recruiting nowBackground: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New HIV vaccines enter human safety trials
⭐️ VACCINE ⭐️ Recruiting nowBackground: Researchers want see if three new HIV (human immunodeficiency virus) vaccines are safe. Two vaccines are carried by live adenoviruses, which are natural and typically cause cold symptoms or an eye infection. Researchers want to see if all the vaccines help fight HIV …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to ease symptoms of rare mast cell disease
Symptom relief OngoingThis is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The st…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can a drug combo stop prostate cancer from coming back?
Disease control OngoingPatients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free surviv…
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
40,000-Person study aims to stop two cancers before they start
Prevention ENROLLING_BY_INVITATIONGastric cancer is a global health threat. Helicobacter pylori is now recognized as the main risk factor that initiates this process; hence, H. pylori eradication has been considered the most effective method to ameliorate the burden of gastric cancer. Serum pepsinogen levels reve…
Sponsor: National Taiwan University Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
Chemo cocktail aimed at zapping pancreatic cysts
Disease control TerminatedThe purpose of this study is to evaluate the efficacy and safety of chemotherapeutic pancreatic cyst ablation using ethanol lavage followed by the infusion of a dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) compared with alcohol-free saline lavage followed by in…
Phase: PHASE3 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill may keep soft tissue sarcoma in check after chemo
Disease control CompletedAnlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and tumor cell pro…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy boosts standard treatment for rectal cancer?
Disease control OngoingThis is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients. Subjects must have received no prior treatment for rectal cancer (chemothe…
Phase: PHASE2 • Sponsor: Baruch Brenner • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Virus and immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control OngoingThe safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the co…
Phase: PHASE1, PHASE2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC
-
Can a short video and counseling session reduce HIV stigma in pregnancy care?
Disease control CompletedThis study will pilot test a brief, scalable intervention called Maisha (Swahili for life), to address HIV stigma for women presenting to antenatal care in Tanzania and male partners who accompany them. The intervention will include: 1) a video and brief counseling that addresses…
Phase: NA • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered donor cells aim to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC